Ajith Nair, MD
Advanced Heart Failure and Transplant Cardiology · Houston, TXNPI 1679747950
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 35.4% of the total. Reporting peaked in 2023 at $26,949 and has fallen 81.0% since, to $5,127 in 2025.
Across 488 payments — averaging $163.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$28K
- Impulse Dynamics (USA) Inc.$21K
- Abbott$21K
- Abiomed$3K
- Medtronic$1K
- Bayer$771
- plus $5K from 33 others
Across 118 payments — averaging $10,588 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$634K
- Janssen Research & Development, LLC$333K
- Impulse Dynamics (USA) Inc.$129K
- Endotronix, Inc.$126K
- Abbott$27K
What the payments were for
- Consulting fees$11,86315%
- Speaking & faculty fees$44,87556%
- Travel & lodging$5,1877%
- Food & beverage$17,43822%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 80 | $28,160 |
| Impulse Dynamics (USA) Inc. | 34 | $21,469 |
| Abbott | 130 | $20,612 |
| Abiomed | 14 | $2,809 |
| Medtronic(2 entities) | 13 | $1,107 |
| Bayer | 29 | $771 |
| United Therapeutics Corporation | 31 | $607 |
| Cvrx, Inc. | 6 | $490 |
| Merck | 25 | $479 |
| Amgen | 20 | $329 |
| Pfizer | 24 | $304 |
| AstraZeneca | 5 | $215 |
| Atricure, Inc. | 2 | $210 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $208 |
| Novartis | 9 | $184 |
| Ancora Heart, Inc. | 5 | $183 |
| Akcea Therapeutics, Inc. | 6 | $166 |
| Bridgebio Pharma, Inc. | 2 | $157 |
| E.r. Squibb & Sons, L.L.C. | 8 | $125 |
| Boston Scientific | 1 | $124 |
| Scpharmaceuticals Inc. | 6 | $109 |
| Sanofi | 1 | $97 |
| Daiichi Sankyo Inc. | 4 | $96 |
| Gilead | 3 | $78 |
| Sandoz | 5 | $64 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Lexicon Pharmaceuticals, Inc. | 3 | $44 |
| Johnson & Johnson | 2 | $39 |
| Kestra Medical Technology Services, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $38 |
| Analog Devices Inc. | 1 | $33 |
| Cardiovascular Systems Inc. | 1 | $29 |
| Acceleron Pharma, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $22 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$41,839
- UPTRAVI$26,335
- OPSUMIT$26,216
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$7,582
- CardioMEMS HF System$7,376
- Impella$2,346
- CARDIOMEMS$1,553
- HeartMate 3 Left Ventricular Assist Device$995
- HeartWare HVAD$862
- Barostim Neo System$346
- HeartMate 3 Left Ventricular Dev$278
- Adempas$235
- ATRICLIP LAA EXCLUSION SYSTEM$210
- SYNERGY ABLATION SYSTEM$210
- HeartMate$161
- OPTIMIZER SMART SYSTEM$148
- FARXIGA$127
- ORENITRAM$125
- Attruby$124
- ROTABLATOR$124
How this compares
$79,556 in reported general payments places this provider in the 75th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 114 | $1,425,741 |
| Tyvaso DpiTreprostinil | 50 | $1,182,961 |
| AdempasRiociguat | 82 | $1,084,999 |
| VyndamaxTafamidis | 34 | $1,034,788 |
| UptraviSelexipag | 27 | $690,429 |
| Orenitram ErTreprostinil Diolamine | 25 | $316,646 |
| EntrestoSacubitril/Valsartan | 164 | $187,052 |
| JardianceEmpagliflozin | 133 | $158,150 |
| EliquisApixaban | 140 | $140,035 |
| Tadalafil | 111 | $124,821 |
| FarxigaDapagliflozin Propanediol | 56 | $73,098 |
| AdcircaTadalafil | 16 | $65,528 |
| Ambrisentan | 41 | $48,434 |
| XareltoRivaroxaban | 19 | $24,233 |
| OzempicSemaglutide | 12 | $22,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $28,160 | $2,116,170141 claims |
| PfizerVyndamax, Eliquis | $304 | $1,174,823174 claims |
| BayerAdempas | $771 | $1,084,99982 claims |
| NovartisEntresto | $184 | $187,052164 claims |
| Boehringer IngelheimJardiance | $38 | $158,150133 claims |
| AstraZenecaFarxiga | $215 | $73,09856 claims |
| United Therapeutics CorporationAdcirca | $607 | $65,52816 claims |
| Johnson & JohnsonXarelto | $39 | $24,23319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Houston
- Barry TrachtenbergHouston$306K
- Arvind BhimarajHouston$216K
- Ashrith GuhaHouston$61K
- Cindy MartinHouston$47K
- Leo SimpsonHouston$30K
- Andrew CivitelloHouston$19K
- Rayan YousefzaiHouston$8K
- Ju KimHouston$7K
- Sana ShoukatHouston$7K
- Janardhana GorthiHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.